Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: Incidence and their prognostic significance

British Journal of Haematology

Volumn 134, Issue 3, 2006, Pages 302-306

  Georgiou, Georgios ^a   Karali, Vasiliki ^a   Zouvelou, Christina ^a   Kyriakou, Elias ^a   Dimou, Maria ^a   Chrisochoou, Stamatis ^a   Greka, Paraskevi ^a   Dufexis, Dimitrios ^a   Vervesou, Elisavet ^a   Dimitriadou, Evaggelia ^a   Efthymiou, Anna ^a   Petrikkos, Loizos ^a   Dima, Katerina ^a   Lilakos, Konstantinos ^a   Panayiotidis, Panayiotis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

FLT3; Myelodysplastic syndrome; Myeloid leukaemia transformation

Indexed keywords

ASPARTIC ACID; FLT3 LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLT3 GENE; GENE; GENE DUPLICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 33745596402     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06171.x     Document Type: Article

References (12)

1. Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Gari, M.A., Peake, I.R., Rees, D.C., Vandenberghe, E., Winship, P. & Reilly, J.T. (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. British Journal of Haematology, 111, 190-195.
2. Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Care, R.S., Peake, I.R. & Reilly, J.T. (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. British Journal of Haematology, 113, 983-988.
3. Bagrinsteva, K., Geisenhof, S., Kern, R., Eichenlaub, S., Reindl, C., Ellwart, J.W., Hiddemann, W. & Spiekermann, K. (2005) FLT3 ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by over expression of Bcl-XL. Blood, 105, 3679-3685.
4. Estey, E.H., Thall, P.F., Cortes, J.E., Giles, F.J., O'Brien, S., Pierce, S.A., Wang, X., Kantarjian, H.M. & Beran, M. (2001) Comparison of idarubisin + ara-C, fludarabine + ara-C, topotecan + ara-C based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, 98, 3575-3583.
5. Karali, V., Dimitriadou, E., Kotsi, P., Georgiou, G., Vervessou, E. & Panayiotidis, P. (2002) ITD and Asp835 mutation of FLT3 gene can occur simultaneously in AML patients [abstract]. Blood, 100, 197.
6. Kottaridis, P.D., Gale, R.E., Frew, M.E., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
7. Sasai, Y.K., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Nakao, M., Nakagawa, H., Fujii, H. & Taniwaki, M. (2001) International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. British Journal of Haematology, 115, 309-312.
8. Side, L.E., Curtiss, N.P., Teel, K., Kratz, C., Wang, P.W., Larson, R.A., Le Beau, M.M. & Shannon, K.M. (2004) Ras, FLT3 and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes, Chromosomes & Cancer, 39, 217-223.
9. Stone, R.M., Klimek, V., De Angelo, D., Klimek, V., Galinsky, I., Estey, E., Nimer, S.D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., Fox, E.A., Neuberg, D., Clark, J., Gilliland, G. & Griffin, J.D. (2003) Oral PKC 412 has activity in patients with mutatnt FLT3 acute myeloid leukemia (AML): a phase II trial. Proceedings of the American Society of Clinical Oncology, 22, 563a.
10. Thiede, C., Steudel, C., Mohr, B., Schaaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002) Analysis of FLT3 activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-4335.
11. INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. British Journal of Haematology, 112, 148-154.
12. Trost, D., Hildebrandt, B., Muller, N., Germing, U. & Royer-Pokora, B. (2004) Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics. Leukemia Research, 28, 171-177.